HMW kininogen, synthesized by hepatocytes, is a multifunctional protein. It is the precursor protein of bradykinin. In addition it is a nonenzymatic cofactor of the contact activation system of factor XI, XII, and prekallikrein and a major extra-cellular cysteine proteinase inhibitor. Kininogen links prekallikrein to a negatively charged surface thereby allowing activation to kallikrein by surface bound Factor alpha-Xlla. Kininogen also forms a complex with Factor XI and accelerates its activation to XIa by alpha-Xlla. Kininogens inhibit systemic proteases which are thought to have a part in various diseases such as cancer, muscular dystrophy and joint disease. The two chain form is prepared by kallikrein digestion of single chain kininogen. Two chain kininogen repurified to remove traces of kallikrein and is kinin free. >95percent pure by SDS-PAGE and shows complete reduction upon incubation with 2-mercaptoethanol. Prepared from plasma found negative by FDA accepted
methods for Anti-HIV1/2, Anti-HTLV I & II, HBsAg, Anti-HCV, Syphilis, HBC Ab, HIV-1 p24 Ag or HIV-1 RNA, HCV RNA and HBV RNA. Donors are screened for CJD (Creutzfeldt-Jakob Disease).